{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-28T11:36:23.093008+00:00","company":{"ticker":"WST","cik":105770,"company_name":"WEST PHARMACEUTICAL SERVICES INC"},"pagination":{"limit":100,"returned":39,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{"contract_counterparty":[{"display_name":"ExxonMobil Product Solutions Company","detail":"supply","count":1,"first_seen":"2023-11-30T23:59:59+00:00","last_seen":"2023-11-30T23:59:59+00:00","evidence_fact_ids":[90853]}]},"facts":[{"fact_type":"executive_change","fact_key":"f71bb330ff","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","payload":{"action":"become","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-08-31","interim":false,"role":"Chair of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Robert F. Friel was appointed as Chair of the Board at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"As of the Start Date, Lead Independent Director Robert F. Friel will become Chair of the Board.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000080","anchor_url":"https://secwatch.observer/filing/0000105770-26-000080#claim-f71bb330ff","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"},{"fact_type":"executive_change","fact_key":"489de7d690","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"retirement","effective_date":"2026-08-31","interim":false,"role":"member of the Board","role_category":"director","successor_name":"Michel Lagarde","successor_named":true},"claim":"Eric M. Green resigned as member of the Board at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-26-000080","anchor_url":"https://secwatch.observer/filing/0000105770-26-000080#claim-489de7d690","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"},{"fact_type":"executive_change","fact_key":"110df09076","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-08-31","interim":false,"role":"member of the Board","role_category":"director","successor_name":null,"successor_named":false},"claim":"Michel Lagarde was appointed as member of the Board at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"As of the Start Date, Mr. Green will resign as a member of the Board and Mr. Lagarde will be appointed as a member of the Board to fill that vacancy.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-26-000080","anchor_url":"https://secwatch.observer/filing/0000105770-26-000080#claim-110df09076","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"},{"fact_type":"executive_change","fact_key":"ed4efa369b","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-06-01T20:32:30+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-08-31","interim":false,"role":"President and Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":true},"claim":"Michel Lagarde was appointed as President and Chief Executive Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On June 1, 2026, the Company announced the appointment of Michel Lagarde as President and Chief Executive Officer of the Company, effective August 31, 2026 (the “Start Date”), to replace Mr. Green in those roles.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-26-000080","anchor_url":"https://secwatch.observer/filing/0000105770-26-000080#claim-ed4efa369b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000080/0000105770-26-000080-index.htm"},{"fact_type":"cyber_incident","fact_key":"6b0d7368b01657198016cd58a93d7bbfa3a812a2","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-05-20T20:04:33+00:00","payload":{"discovery_date":"2026-05-04","impact_text":"no material impact on financial guidance; fully operational","item_codes_triggered":["1.05"],"materiality_status":"not_material","nature_text":"data exfiltrated by unauthorized party and systems encrypted"},"claim":"WEST PHARMACEUTICAL SERVICES INC disclosed a cybersecurity incident: data exfiltrated by unauthorized party and systems encrypted. Impact: no material impact on financial guidance; fully operational. Company determined it not material. Discovered 2026-05-04.","evidence_excerpt":"Based on the investigation to date and information currently available, the Company believes that the incident has not had, and is not reasonably likely to have, a material impact on the Company’s 2026 second-quarter and full-year financial guidance.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000077","anchor_url":"https://secwatch.observer/filing/0000105770-26-000077#claim-6b0d7368b01657198016cd58a93d7bbfa3a812a2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000077/0000105770-26-000077-index.htm"},{"fact_type":"cyber_incident","fact_key":"d0feab9e028cc12a18352a2eb4810f202d8f2a10","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-05-11T21:06:38+00:00","payload":{"discovery_date":"2026-05-04","impact_text":"Temporarily disrupted business operations globally; core enterprise systems restored; shipping, receiving, and manufacturing restarted at some sites with restoration of remaining sites in process; material impact on financial condition and results of operations not yet determined","item_codes_triggered":["1.05"],"materiality_status":"determined_material","nature_text":"Cybersecurity attack involving data exfiltration by an unauthorized party and encryption of certain systems"},"claim":"WEST PHARMACEUTICAL SERVICES INC disclosed a cybersecurity incident: Cybersecurity attack involving data exfiltration by an unauthorized party and encryption of certain systems. Impact: Temporarily disrupted business operations globally; core enterprise systems restored; shipping, receiving, and manufacturing restarted at some sites with restoration of remaining sites in process; material impact on financial condition and results of operations not yet determined. Company determined it material. Discovered 2026-05-04.","evidence_excerpt":"On May 7, 2026, West Pharmaceutical Services, Inc. (the “Company”) determined that the Company has experienced a material cybersecurity attack, in which certain data was exfiltrated by an unauthorized party and certain systems were encrypted.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000068","anchor_url":"https://secwatch.observer/filing/0000105770-26-000068#claim-d0feab9e028cc12a18352a2eb4810f202d8f2a10","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000068/0000105770-26-000068-index.htm"},{"fact_type":"shareholder_vote","fact_key":"3ff2b08147df01cfff4956c639ff39f3bea1bb3e","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-04","outcome":"failed","proposal_text":"Shareholder proposal regarding an Independent Board Chair Policy","proposal_type":"other","results":[{"broker_non_votes":"2,242,885","subject":null,"votes_abstain":"112,824","votes_against":"34,245,125","votes_for":"29,592,488","votes_withheld":null}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders rejected Shareholder proposal regarding an Independent Board Chair Policy at the 2026-05-04 meeting.","evidence_excerpt":"Proposal 4: The shareholder proposal regarding an Independent Board Chair Policy was not approved as set forth below.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000056","anchor_url":"https://secwatch.observer/filing/0000105770-26-000056#claim-3ff2b08147df01cfff4956c639ff39f3bea1bb3e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000056/0000105770-26-000056-index.htm"},{"fact_type":"shareholder_vote","fact_key":"0e3641659bf80d685e41aca0f5c25d24a226ddf4","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-04","outcome":"passed","proposal_text":"Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026","proposal_type":"auditor_ratification","results":[{"broker_non_votes":null,"subject":null,"votes_abstain":"127,689","votes_against":"7,556,514","votes_for":"58,509,119","votes_withheld":null}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026 at the 2026-05-04 meeting.","evidence_excerpt":"Proposal 3: The appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the 2026 fiscal year was ratified as set forth below.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000056","anchor_url":"https://secwatch.observer/filing/0000105770-26-000056#claim-0e3641659bf80d685e41aca0f5c25d24a226ddf4","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000056/0000105770-26-000056-index.htm"},{"fact_type":"shareholder_vote","fact_key":"634c2b434c56d11e5a6be19432c4b7985e00b028","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-04","outcome":"passed","proposal_text":"Non-binding advisory vote to approve the compensation of the Company's named executive officers","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,242,885","subject":null,"votes_abstain":"80,429","votes_against":"3,762,206","votes_for":"60,107,802","votes_withheld":null}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Non-binding advisory vote to approve the compensation of the Company's named executive officers at the 2026-05-04 meeting.","evidence_excerpt":"Proposal 2: The non-binding advisory vote to approve the compensation of the Company's named executive officers was approved as set forth below.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000056","anchor_url":"https://secwatch.observer/filing/0000105770-26-000056#claim-634c2b434c56d11e5a6be19432c4b7985e00b028","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000056/0000105770-26-000056-index.htm"},{"fact_type":"shareholder_vote","fact_key":"84d1bb5c6fce6e48acc7ef7251f6ab382b9b881f","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-05-05T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2026-05-04","outcome":"passed","proposal_text":"Election of eleven nominees as directors to serve until the 2027 Annual Meeting of Shareholders","proposal_type":"director_election","results":[{"broker_non_votes":"2,242,885","subject":"Mark A. Buthman","votes_abstain":"34,356","votes_against":null,"votes_for":"62,394,975","votes_withheld":"1,521,106"},{"broker_non_votes":"2,242,885","subject":"William F. Feehery","votes_abstain":"33,844","votes_against":null,"votes_for":"61,427,391","votes_withheld":"2,489,202"},{"broker_non_votes":"2,242,885","subject":"Robert F. Friel","votes_abstain":"32,005","votes_against":null,"votes_for":"62,396,755","votes_withheld":"1,521,677"},{"broker_non_votes":"2,242,885","subject":"Eric M. Green","votes_abstain":"483,977","votes_against":null,"votes_for":"58,892,532","votes_withheld":"4,573,928"},{"broker_non_votes":"2,242,885","subject":"Janet B. Haugen","votes_abstain":"28,839","votes_against":null,"votes_for":"61,934,409","votes_withheld":"1,987,189"},{"broker_non_votes":"2,242,885","subject":"Molly E. Joseph","votes_abstain":"63,126","votes_against":null,"votes_for":"61,545,956","votes_withheld":"2,341,355"},{"broker_non_votes":"2,242,885","subject":"Deborah L. V. Keller","votes_abstain":"358,883","votes_against":null,"votes_for":"57,992,162","votes_withheld":"5,599,392"},{"broker_non_votes":"2,242,885","subject":"Myla P. Lai-Goldman","votes_abstain":"31,754","votes_against":null,"votes_for":"61,523,642","votes_withheld":"2,395,041"},{"broker_non_votes":"2,242,885","subject":"Stephen H. Lockhart","votes_abstain":"47,217","votes_against":null,"votes_for":"63,432,380","votes_withheld":"470,840"},{"broker_non_votes":"2,242,885","subject":"Douglas A. Michels","votes_abstain":"39,489","votes_against":null,"votes_for":"60,240,141","votes_withheld":"3,670,807"},{"broker_non_votes":"2,242,885","subject":"Paolo Pucci","votes_abstain":"39,237","votes_against":null,"votes_for":"62,930,048","votes_withheld":"981,152"}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Election of eleven nominees as directors to serve until the 2027 Annual Meeting of Shareholders at the 2026-05-04 meeting.","evidence_excerpt":"Proposal 1: The eleven nominees, as set forth below and in the Company's 2026 Proxy Statement, were elected as directors, each to serve until the 2027 Annual Meeting of Shareholders.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000056","anchor_url":"https://secwatch.observer/filing/0000105770-26-000056#claim-84d1bb5c6fce6e48acc7ef7251f6ab382b9b881f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000056/0000105770-26-000056-index.htm"},{"fact_type":"earnings_release","fact_key":"d938775c856c1a397898f3a92c94192ec630c80a","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2026-04-23T23:59:59+00:00","payload":{"eps_text":"$1.92","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the first quarter of 2026","report_date":"2026-04-23","result_type":"reported_results","revenue_text":"$844.9 million"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported the first quarter of 2026 results: revenue $844.9 million, EPS $1.92. Guidance raised.","evidence_excerpt":"West Reports First-Quarter 2026 Results – Strong Start to the Year and Raising Full Year Revenue and EPS guidance Exton, PA, April 23, 2026 – West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the first quarter of 2026. First-Quarter Summary (comparisons to prior-year period) • Net sales of $844.9 million increased 21.0%; organic growth was 15.3%. • Diluted earnings per share (\"EPS\") of $1.92 increased 56.1%.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-26-000047","anchor_url":"https://secwatch.observer/filing/0000105770-26-000047#claim-d938775c856c1a397898f3a92c94192ec630c80a","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/0000105770-26-000047-index.htm"},{"fact_type":"executive_change","fact_key":"6b8c7e4d7b","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2025-04-24T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-05-05","interim":false,"role":"Senior Vice President, Chief Proprietary Segment Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Shane Campbell was appointed as Senior Vice President, Chief Proprietary Segment Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On April 24, 2025, the Company announced that it had appointed Shane Campbell to serve as Senior Vice President, Chief Proprietary Segment Officer, effective May 5, 2025","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-25-000031","anchor_url":"https://secwatch.observer/filing/0000105770-25-000031#claim-6b8c7e4d7b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000031/0000105770-25-000031-index.htm"},{"fact_type":"executive_change","fact_key":"fbbdfd6972","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2025-04-24T23:59:59+00:00","payload":{"action":"intends to retire","action_category":"departure","departure_tone":"retirement","effective_date":null,"interim":false,"role":"Senior Vice President & Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Bernard Birkett departed as Senior Vice President & Chief Financial Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On April 22, 2025, Mr. Bernard Birkett notified West Pharmaceutical Services, Inc. (the “Company”) of his intention to retire as Senior Vice President & Chief Financial Officer later this year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-25-000031","anchor_url":"https://secwatch.observer/filing/0000105770-25-000031#claim-fbbdfd6972","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000031/0000105770-25-000031-index.htm"},{"fact_type":"executive_change","fact_key":"a399613427","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2025-04-14T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2025-03-07","interim":false,"role":"Senior Vice President and Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Cindy Reiss-Clark departed as Senior Vice President and Chief Commercial Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, former Senior Vice President and Chief Commercial Officer, departed from the Company effective that same date.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-25-000022","anchor_url":"https://secwatch.observer/filing/0000105770-25-000022#claim-a399613427","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000022/0000105770-25-000022-index.htm"},{"fact_type":"executive_change","fact_key":"01849bc3af","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2025-03-11T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2025-03-07","interim":true,"role":"Senior Vice President and Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Cindy Reiss-Clark departed as Senior Vice President and Chief Commercial Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On March 7, 2025, West Pharmaceutical Services, Inc. (the “Company”) announced that Cindy Reiss-Clark, Senior Vice President and Chief Commercial Officer, has departed the Company, effective the same day.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-25-000019","anchor_url":"https://secwatch.observer/filing/0000105770-25-000019#claim-01849bc3af","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577025000019/0000105770-25-000019-index.htm"},{"fact_type":"executive_change","fact_key":"fadc7cc5da","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-10-07T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2024-12-31","interim":false,"role":"Senior Vice President & Chief Technology Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Silji Abraham resigned as Senior Vice President & Chief Technology Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On October 1, 2024, Silji Abraham, Senior Vice President & Chief Technology Officer of West Pharmaceutical Services, Inc. (the “Company”), notified the Company that he intends to resign, effective December 31, 2024, to pursue other interests.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-24-000071","anchor_url":"https://secwatch.observer/filing/0000105770-24-000071#claim-fadc7cc5da","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000071/0000105770-24-000071-index.htm"},{"fact_type":"executive_change","fact_key":"72efcae078","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-04-26T23:59:59+00:00","payload":{"action":"role change","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2024-05-01","interim":false,"role":"Chief Financial Officer","role_category":"cfo","successor_name":null,"successor_named":false},"claim":"Bernard Birkett changed role as Chief Financial Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"Effective May 1, 2024, Mr. Birkett’s title will be solely Chief Financial Officer (“CFO”), where he will retain financial oversight for both Business Segments, operational oversight of our strategic sourcing function and be involved in key operational issues together with other members of our executive team.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-24-000035","anchor_url":"https://secwatch.observer/filing/0000105770-24-000035#claim-72efcae078","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000035/0000105770-24-000035-index.htm"},{"fact_type":"earnings_release","fact_key":"9448abb4b5cefd0c55ddb4f2764ea4be12ec54f7","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-04-25T23:59:59+00:00","payload":{"eps_text":"1.55","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first-quarter 2024","report_date":"2024-04-25","result_type":"reported_results","revenue_text":"695.4 million"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2024 results: revenue 695.4 million, EPS 1.55.","evidence_excerpt":"Net sales of $695.4 million declined 3.0%; organic net sales also declined by 3.0%. • Reported-diluted EPS of $1.55 declined by 16.2%.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-24-000025","anchor_url":"https://secwatch.observer/filing/0000105770-24-000025#claim-9448abb4b5cefd0c55ddb4f2764ea4be12ec54f7","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000025/0000105770-24-000025-index.htm"},{"fact_type":"earnings_release","fact_key":"76cf0ba3000fce080d327d06190fe61ee33885cf","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-02-15T23:59:59+00:00","payload":{"eps_text":"adjusted-diluted EPS in a range of $7.50 to $7.75","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Full-year 2024","report_date":"2024-02-15","result_type":"preliminary_results","revenue_text":"in a range of $3.000 billion to $3.025 billion"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported Full-year 2024 results: revenue in a range of $3.000 billion to $3.025 billion, EPS adjusted-diluted EPS in a range of $7.50 to $7.75. Guidance initiated.","evidence_excerpt":"The Company is introducing full-year 2024 financial guidance of net sales in a range of $3.000 billion to $3.025 billion and adjusted-diluted EPS in a range of $7.50 to $7.75.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-24-000009","anchor_url":"https://secwatch.observer/filing/0000105770-24-000009#claim-76cf0ba3000fce080d327d06190fe61ee33885cf","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm"},{"fact_type":"earnings_release","fact_key":"e00931739e170190963f79035e4425764e703729","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2024-02-15T23:59:59+00:00","payload":{"eps_text":"$7.88","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth-quarter and full-year 2023","report_date":"2024-02-15","result_type":"reported_results","revenue_text":"$2.950 billion"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2023 results: revenue $2.950 billion, EPS $7.88. Guidance reaffirmed.","evidence_excerpt":"full-year 2023 and introduced full-year 2024 financial guidance. Fourth-Quarter and Full-Year 2023 Summary (comparisons to prior-year period) • Fourth-quarter 2023 net sales of $732.0 million grew 3.3%; organic net sales growth was 1.4%. Full-year 2023 net sales of $2.950 billion grew 2.2%; organic net sales growth was 1.6%. • Fourth-quarter 2023 reported-diluted EPS","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-24-000009","anchor_url":"https://secwatch.observer/filing/0000105770-24-000009#claim-e00931739e170190963f79035e4425764e703729","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577024000009/0000105770-24-000009-index.htm"},{"fact_type":"material_agreement","fact_key":"899be804779ce9fe956de2504c621c0958e248f3","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-11-30T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"global master supply agreement","agreement_type":"supply","counterparty":"ExxonMobil Product Solutions Company","effective_date":"2023-11-27","item_codes_triggered":["1.01"],"value_text":null},"claim":"WEST PHARMACEUTICAL SERVICES INC amended global master supply agreement with ExxonMobil Product Solutions Company (effective 2023-11-27).","evidence_excerpt":"On November 27, 2023, West Pharmaceutical Services, Inc. (the “Company”) executed an amendment to the global master supply agreement (the “Amendment”) with ExxonMobil Product Solutions Company (“EMPSC”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-23-000075","anchor_url":"https://secwatch.observer/filing/0000105770-23-000075#claim-899be804779ce9fe956de2504c621c0958e248f3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000075/0000105770-23-000075-index.htm"},{"fact_type":"earnings_release","fact_key":"89c33c6ee9b70cb1f8162a0a380866734307ad33","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-10-26T23:59:59+00:00","payload":{"eps_text":"Reported-diluted EPS of $2.14 increased 34.6%.","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Third-Quarter 2023","report_date":"2023-10-26","result_type":"reported_results","revenue_text":"Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%."},"claim":"WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2023 results: revenue Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%., EPS Reported-diluted EPS of $2.14 increased 34.6%..","evidence_excerpt":"West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 26, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2023, updated full-year 2023 financial guidance and declared a fourth-quarter 2023 dividend. Third-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%. • Reported-diluted EPS of $2.14 increased 34.6%.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-23-000064","anchor_url":"https://secwatch.observer/filing/0000105770-23-000064#claim-89c33c6ee9b70cb1f8162a0a380866734307ad33","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/0000105770-23-000064-index.htm"},{"fact_type":"earnings_release","fact_key":"ed1ea59a8d23905a281c64dd63f24722c09c998c","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-07-27T23:59:59+00:00","payload":{"eps_text":"$2.06","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"second-quarter 2023","report_date":"2023-07-27","result_type":"reported_results","revenue_text":"$753.8 million"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported second-quarter 2023 results: revenue $753.8 million, EPS $2.06. Guidance raised.","evidence_excerpt":"West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance. Second-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $753.8 million declined 2.3%; organic net sales declined 2.5%. • Reported-diluted EPS of $2.06, compared to $2.48 in the same period last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-23-000043","anchor_url":"https://secwatch.observer/filing/0000105770-23-000043#claim-ed1ea59a8d23905a281c64dd63f24722c09c998c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000043/0000105770-23-000043-index.htm"},{"fact_type":"shareholder_vote","fact_key":"cf990a361b5ebe19fa1ea7e2cd3eccca92eb3d93","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-04-25","outcome":"failed","proposal_text":"Shareholder proposal regarding fair elections","proposal_type":"other","results":[{"broker_non_votes":"2,070,313","subject":null,"votes_abstain":"143,490","votes_against":"58,183,766","votes_for":"7,047,212","votes_withheld":"0"}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders rejected Shareholder proposal regarding fair elections at the 2023-04-25 meeting.","evidence_excerpt":"Proposal 5: Our shareholders rejected the shareholder proposal regarding fair elections by the following vote: For Against Abstain Broker Non-Votes 7,047,212 58,183,766 143,490 2,070,313","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-23-000026","anchor_url":"https://secwatch.observer/filing/0000105770-23-000026#claim-cf990a361b5ebe19fa1ea7e2cd3eccca92eb3d93","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000026/0000105770-23-000026-index.htm"},{"fact_type":"shareholder_vote","fact_key":"4b53d2d5fe9eec9fa8c84ad227afc3fe806d6edb","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-04-25","outcome":"passed","proposal_text":"Advisory vote on frequency of votes on executive officer compensation","proposal_type":"say_on_pay_frequency","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"33,838","votes_against":"15,575","votes_for":"64,486,696","votes_withheld":"0"}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Advisory vote on frequency of votes on executive officer compensation at the 2023-04-25 meeting.","evidence_excerpt":"Proposal 4: Our shareholders approved, on an advisory basis, the frequency of votes on executive officer compensation by the following vote: 1 Year 2 Years 3 Years Abstain 64,486,696 15,575 838,359 33,838","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-23-000026","anchor_url":"https://secwatch.observer/filing/0000105770-23-000026#claim-4b53d2d5fe9eec9fa8c84ad227afc3fe806d6edb","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000026/0000105770-23-000026-index.htm"},{"fact_type":"shareholder_vote","fact_key":"629e96a41e9c6bcfed496538a64c12f2c8cc0c82","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-04-25","outcome":"passed","proposal_text":"Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm","proposal_type":"auditor_ratification","results":[{"broker_non_votes":"0","subject":null,"votes_abstain":"24,451","votes_against":"5,198,468","votes_for":"62,221,862","votes_withheld":"0"}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm at the 2023-04-25 meeting.","evidence_excerpt":"Proposal 3: Our shareholders ratified the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the 2023 fiscal year by the following vote: For Against Abstain 62,221,862 5,198,468 24,451","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-23-000026","anchor_url":"https://secwatch.observer/filing/0000105770-23-000026#claim-629e96a41e9c6bcfed496538a64c12f2c8cc0c82","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000026/0000105770-23-000026-index.htm"},{"fact_type":"shareholder_vote","fact_key":"a1a916734eeeb711ab5ff143ae1b57d08da324ab","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-04-25","outcome":"passed","proposal_text":"Advisory vote on named executive officer compensation","proposal_type":"say_on_pay","results":[{"broker_non_votes":"2,070,313","subject":null,"votes_abstain":"88,997","votes_against":"2,954,865","votes_for":"62,330,606","votes_withheld":"0"}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Advisory vote on named executive officer compensation at the 2023-04-25 meeting.","evidence_excerpt":"Proposal 2: Our shareholders approved, on an advisory basis, our named executive officer compensation by the following vote: For Against Abstain Broker Non-Votes 62,330,606 2,954,865 88,997 2,070,313","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-23-000026","anchor_url":"https://secwatch.observer/filing/0000105770-23-000026#claim-a1a916734eeeb711ab5ff143ae1b57d08da324ab","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000026/0000105770-23-000026-index.htm"},{"fact_type":"shareholder_vote","fact_key":"92995b0e498dd7c8fad668c0d4097dca7142fb8c","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-28T23:59:59+00:00","payload":{"item_codes_triggered":["5.07"],"meeting_date":"2023-04-25","outcome":"passed","proposal_text":"Election of directors","proposal_type":"director_election","results":[{"broker_non_votes":"2,070,313","subject":"Mark A. Buthman","votes_abstain":"0","votes_against":"113,624","votes_for":"64,658,097","votes_withheld":"602,747"},{"broker_non_votes":"2,070,313","subject":"William F. Feehery","votes_abstain":"0","votes_against":"2,878,944","votes_for":"55,002,437","votes_withheld":"7,493,087"},{"broker_non_votes":"2,070,313","subject":"Robert F. Friel","votes_abstain":"0","votes_against":"969,217","votes_for":"62,935,621","votes_withheld":"1,469,630"},{"broker_non_votes":"2,070,313","subject":"Eric M. Green","votes_abstain":"0","votes_against":"281,325","votes_for":"60,170,150","votes_withheld":"4,922,993"},{"broker_non_votes":"2,070,313","subject":"Thomas W. Hofmann","votes_abstain":"0","votes_against":"462,430","votes_for":"61,851,061","votes_withheld":"3,060,977"},{"broker_non_votes":"2,070,313","subject":"Molly E. Joseph","votes_abstain":"0","votes_against":"63,822","votes_for":"64,827,643","votes_withheld":"483,003"},{"broker_non_votes":"2,070,313","subject":"Deborah L. V. Keller","votes_abstain":"0","votes_against":"936,277","votes_for":"62,842,349","votes_withheld":"1,595,842"},{"broker_non_votes":"2,070,313","subject":"Myla P. Lai-Goldman","votes_abstain":"0","votes_against":"69,433","votes_for":"65,133,007","votes_withheld":"172,028"},{"broker_non_votes":"2,070,313","subject":"Stephen H. Lockhart","votes_abstain":"0","votes_against":"51,507","votes_for":"65,094,280","votes_withheld":"228,681"},{"broker_non_votes":"2,070,313","subject":"Douglas A. Michels","votes_abstain":"0","votes_against":"441,377","votes_for":"62,752,334","votes_withheld":"2,180,757"},{"broker_non_votes":"2,070,313","subject":"Paolo Pucci","votes_abstain":"0","votes_against":"968,520","votes_for":"62,937,309","votes_withheld":"1,468,639"}]},"claim":"WEST PHARMACEUTICAL SERVICES INC shareholders approved Election of directors at the 2023-04-25 meeting.","evidence_excerpt":"Proposal 1: Our shareholders elected the following directors to serve on our Board until the 2024 Annual Meeting of Shareholders by the following vote: Name For Against Abstain Broker Non-Votes Mark A. Buthman 64,658,097 113,624 602,747 2,070,313 William F. Feehery 55,002,437 2,878,944 7,493,087 2,070,313 Robert F. Friel 62,935,621 969,217 1,469,630 2,070,313 Eric M. Green 60,170,150 281,325 4,922,993 2,070,313 Thomas W. Hofmann 61,851,061 462,430 3,060,977 2,070,313 Molly E. Joseph 64,827,643 63,822 483,003 2,070,313 Deborah L. V. Keller 62,842,349 936,277 1,595,842 2,070,313 Myla P. Lai-Goldman 65,133,007 69,433 172,028 2,070,313 Stephen H. Lockhart 65,094,280 51,507 228,681 2,070,313 Douglas A. Michels 62,752,334 441,377 2,180,757 2,070,313 Paolo Pucci 62,937,309 968,520 1,468,639 2,070,313","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-23-000026","anchor_url":"https://secwatch.observer/filing/0000105770-23-000026#claim-92995b0e498dd7c8fad668c0d4097dca7142fb8c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000026/0000105770-23-000026-index.htm"},{"fact_type":"earnings_release","fact_key":"c7fef759cb9ff45210e753e8bb81a38ad692dc45","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-04-27T23:59:59+00:00","payload":{"eps_text":"$1.85","guidance_signal":"raised","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"first-quarter 2023","report_date":"2023-04-27","result_type":"reported_results","revenue_text":"$716.6 million"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported first-quarter 2023 results: revenue $716.6 million, EPS $1.85. Guidance raised.","evidence_excerpt":"West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the first-quarter 2023 and updated full-year 2023 financial guidance. First-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $716.6 million declined 0.5%; organic sales growth was 2.3%. • Reported-diluted EPS of $1.85 declined by 19.2%. • Adjusted-diluted EPS of $1.98 declined by 13.9%. • The Company is updating full-year 2023 financial guidance of net sales to a new range of $2.965 billion to $2.990 billion compared to a prior range of $2.935 billion to $2.960 billion. • The Company is updating full-year 2023 financial guidance of adjusted-diluted EPS to a new range of $7.50 to $7.65, compared to a prior range of $7.25 to $7.40.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-23-000018","anchor_url":"https://secwatch.observer/filing/0000105770-23-000018#claim-c7fef759cb9ff45210e753e8bb81a38ad692dc45","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000018/0000105770-23-000018-index.htm"},{"fact_type":"earnings_release","fact_key":"0e11b253d22703b1afeeed56321028f4d5b3154d","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-02-16T23:59:59+00:00","payload":{"eps_text":"$7.25 to $7.40","guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"full-year 2023","report_date":"2023-02-16","result_type":"guidance_update","revenue_text":"$2.935 billion to $2.960 billion"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported full-year 2023 results: revenue $2.935 billion to $2.960 billion, EPS $7.25 to $7.40. Guidance initiated.","evidence_excerpt":"The Company is introducing full-year 2023 financial guidance of net sales in a range of $2.935 billion to $2.960 billion and adjusted-diluted EPS in a range of $7.25 to $7.40.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-23-000004","anchor_url":"https://secwatch.observer/filing/0000105770-23-000004#claim-0e11b253d22703b1afeeed56321028f4d5b3154d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm"},{"fact_type":"earnings_release","fact_key":"18e29004bd62023241357820d8cd00235ff84df9","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2023-02-16T23:59:59+00:00","payload":{"eps_text":null,"guidance_signal":"initiated","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"the fourth-quarter and full-year 2022","report_date":"2023-02-16","result_type":"reported_results","revenue_text":"$708.7 million"},"claim":"WEST PHARMACEUTICAL SERVICES INC reported the fourth-quarter and full-year 2022 results: revenue $708.7 million. Guidance initiated.","evidence_excerpt":"West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2022 and introduced full-year 2023 financial guidance. Fourth-Quarter and Full-Year 2022 Summary (comparisons to prior-year period) • Fourth-quarter 2022 net sales of $708.7 million declined 3.0%; organic net sales growth was 2.6%","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0000105770-23-000004","anchor_url":"https://secwatch.observer/filing/0000105770-23-000004#claim-18e29004bd62023241357820d8cd00235ff84df9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577023000004/0000105770-23-000004-index.htm"},{"fact_type":"earnings_release","fact_key":"d291f34a82a1dbf515925108bb19098c1a0ed82d","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-10-27T23:59:59+00:00","payload":{"eps_text":"2.03","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":null,"period_text":"Third-Quarter 2022","report_date":"2022-10-27","result_type":"reported_results","revenue_text":null},"claim":"WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2022 results: EPS 2.03.","evidence_excerpt":"(610) 594-3054 Quintin.Lai@westpharma.com Michele.Polinsky@westpharma.com\n\n--- EX-99.2 (EX-99.2) ---\n\nfinalwestq3oct2022 1 Third-Quarter 2022 Third Quarter Overall Net Sales $686.9M | 2.8% Diluted Earnings Per Share: $1.59 Adjusted Diluted Earnings Per Share: $2.03 Eric M. Green President and Chief Executive Officer, Chair of the Board West Pharmaceutical","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-22-000050","anchor_url":"https://secwatch.observer/filing/0000105770-22-000050#claim-d291f34a82a1dbf515925108bb19098c1a0ed82d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000050/0000105770-22-000050-index.htm"},{"fact_type":"executive_change","fact_key":"6bad83e67f","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-07-27T23:59:59+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-07-26","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Stephen Lockhart was elected as Director at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On July 26, 2022, West Pharmaceutical Services, Inc. (the \"Company\") elected Stephen Lockhart, M.D., Ph.D., to its Board of Directors (the \"Board\") as its newest member.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0000105770-22-000038","anchor_url":"https://secwatch.observer/filing/0000105770-22-000038#claim-6bad83e67f","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000038/0000105770-22-000038-index.htm"},{"fact_type":"executive_change","fact_key":"7e4eab38ec","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-05-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-12","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Cindy Reiss-Clark was appointed as Chief Commercial Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"The Company has also announced other leadership changes and additions, including the appointment of Cindy Reiss-Clark as the Chief Commercial Officer","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-22-000021","anchor_url":"https://secwatch.observer/filing/0000105770-22-000021#claim-7e4eab38ec","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000021/0000105770-22-000021-index.htm"},{"fact_type":"executive_change","fact_key":"2f8ee4e757","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-05-12T23:59:59+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":null,"interim":false,"role":"Senior Vice President, Chief Global Operations and Supply Chain Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"David Montecalvo resigned as Senior Vice President, Chief Global Operations and Supply Chain Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"After six years of dedicated service, the Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo, has announced his resignation to pursue other interests, with a departure date of July 2022.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-22-000021","anchor_url":"https://secwatch.observer/filing/0000105770-22-000021#claim-2f8ee4e757","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000021/0000105770-22-000021-index.htm"},{"fact_type":"executive_change","fact_key":"b229f33d6c","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-05-12T23:59:59+00:00","payload":{"action":"appointed","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-05-12","interim":false,"role":"Chief Financial and Operations Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Bernard J. Birkett was appointed as Chief Financial and Operations Officer at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"On May 12, 2022, West Pharmaceutical Services, Inc. (the “Company” or \"West\") announced the appointment of Bernard J. Birkett, Chief Financial Officer, to a newly combined position of Chief Financial and Operations Officer.","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0000105770-22-000021","anchor_url":"https://secwatch.observer/filing/0000105770-22-000021#claim-b229f33d6c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000010577022000021/0000105770-22-000021-index.htm"},{"fact_type":"executive_change","fact_key":"8871f23da8","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-02-28T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2022-05-24","interim":false,"role":"Lead Independent Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Paolo Pucci was appointed as Lead Independent Director at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"West has appointed Paolo Pucci as the Lead Independent Director for the Board of Directors, effective at the Annual Meeting.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-004277","anchor_url":"https://secwatch.observer/filing/0001628280-22-004277#claim-8871f23da8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000162828022004277/0001628280-22-004277-index.htm"},{"fact_type":"executive_change","fact_key":"c3f8c244e9","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-02-28T23:59:59+00:00","payload":{"action":"assume the additional responsibility of Chair","action_category":"role_change","departure_tone":"not_applicable","effective_date":"2022-05-24","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Eric M. Green changed role as Chairman of the Board at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"Eric M. Green, President and Chief Executive Officer (\"CEO\"), will assume the additional responsibility of Chair of the Company's Board upon Mr. Zenner's retirement.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-004277","anchor_url":"https://secwatch.observer/filing/0001628280-22-004277#claim-c3f8c244e9","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000162828022004277/0001628280-22-004277-index.htm"},{"fact_type":"executive_change","fact_key":"187c14a9e0","cik":105770,"ticker":"WST","company_name":"WEST PHARMACEUTICAL SERVICES INC","filed_at":"2022-02-28T23:59:59+00:00","payload":{"action":"retire and not stand for re-election","action_category":"departure","departure_tone":"retirement","effective_date":"2022-05-24","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":"Eric M. Green","successor_named":true},"claim":"Patrick Zenner departed as Chairman of the Board at WEST PHARMACEUTICAL SERVICES INC.","evidence_excerpt":"Patrick Zenner informed West Pharmaceutical Services, Inc. (the “Company”) on February 22, 2022, of his intention to retire and not to stand for re-election as Chairman to the Company’s Board of Directors","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001628280-22-004277","anchor_url":"https://secwatch.observer/filing/0001628280-22-004277#claim-187c14a9e0","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/105770/000162828022004277/0001628280-22-004277-index.htm"}]}